


CLAIMS

1. Compound of formula (IV)



5

(I)

where

Het¹ Het¹ is pyrazolyl, which may be unsubstituted or mono-, di- or trisubstituted, independently of one another, by Hal or A,

A in each case independently denotes unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 C atoms, where, independently of one another, 1, 2, 3, 4, or 5 H atoms may be replaced by Hal,

Hal denotes F, Cl, Br or I,

HET is selected from: 3-difluoromethoxy-5-fluoropyridin-4-yl, 3-fluoro-5-methoxypyridin-4-yl, 3-fluoro-5-fluoromethoxypyridin-4-yl, 3-fluoro-5-(trideuteriomethoxy)pyridin-4-yl,


and/or pharmaceutically usable salt or solvate thereof.

2. Compound of the formula (IV) according to Claim 1, where Het¹ is selected from: 1H-pyrazol-4-yl, 2H-pyrazol-3-yl, 1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-4-yl, 3-methyl-1H-pyrazol-4-yl, 5-methyl-1H-pyrazol-3-yl, 4-methyl-1H-pyrazol-3-yl, 1-fluoromethyl-1H-pyrazol-4-yl, 1-difluoromethyl-1H-pyrazol-4-yl, 1,3-dimethyl-1H-pyrazol-4-yl, 1-ethyl-1H-pyrazol-4-yl, 1-ethyl-3-methyl-1H-pyrazolyl, 3-fluoro-1-methyl-1H-pyrazol-4-yl,

and/or pharmaceutically usable salt or solvate thereof.


25

3. Compound according to Claim 1, which is




- 5 and/or pharmaceutically usable salt or solvate thereof.

4. Compound according to Claim 1, which is




- 10 and/or pharmaceutically usable salt or solvate thereof.

5. Compound according to Claim 1, which is




- 15 and/or pharmaceutically usable salt or solvate thereof.

6. Compound according to Claim 1, which is




- 5 and/or pharmaceutically usable salt or solvate thereof.

7. Compound according to Claim 1, which is




- 10 and/or pharmaceutically usable salt or solvate thereof.

8. Compound according to Claim 1, which is




- 15 and/or pharmaceutically usable salt or solvate thereof.

9. Compound according to Claim 1, which is




- 5 and/or pharmaceutically usable salt or solvate thereof.

10. Compound according to Claim 1, which is




- 10 and/or pharmaceutically usable salt or solvate thereof.

11. Compound according to Claim 1, which is




- 15 and/or pharmaceutically usable salt or solvate thereof.

12. Compound according to Claim 1, which is




5 and/or pharmaceutically usable salt or solvate thereof.

13. Compound according to Claim 1, which is




10 and/or pharmaceutically usable salt or solvate thereof.

14. Compound according to Claim 1, which is




15 and/or pharmaceutically usable salt or solvate thereof.

15. Compound according to Claim 1, which is



and/or pharmaceutically usable salt or solvate thereof.

- 5 16. Compound according to Claim 1, which is



and/or pharmaceutically usable salt or solvate thereof.

10

17. Compound according to one of Claims 1 to 16 and/or pharmaceutically usable salt or solvate thereof, for use as medicament.

18. Use of a compound according to one of Claims 1 to 16 and/or pharmaceutically usable salt or solvate thereof, for use in the treatment of cancer, tumours and/or metastases.

15

19. The use of a compound and/or pharmaceutically usable salt or solvate thereof according to Claim 18, wherein the treatment is to be used in combination with radiotherapy.

20

20. The use of a compound and/or pharmaceutically usable salt or solvate thereof according to Claim 18, wherein the treatment is to be used in combination with at least one anticancer agent.

25

21. The use of a compound and/or pharmaceutically usable salt or solvate thereof according to Claim 18, 19 or 20, where the tumour is selected from the group of diseases of squamous epithelium, bladder, stomach, kidneys, head, neck, oesophagus, cervix, thyroid, intestine, bone, liver, brain, prostate, urogenital tract, lymphatic system, larynx, lung, skin, blood and immune system, and/or the cancer is selected from the group of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, intestinal carcinoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma
22. Pharmaceutical composition comprising an effective amount of at least one compound according to one of Claims 1 to 16 and/or a pharmaceutically usable salt or solvate thereof, optionally together with at least one pharmaceutically tolerated excipient.
23. Pharmaceutical composition according to Claim 22, furthermore comprising at least one anticancer agent.
24. The use of a kit consisting of separate packs of
(a) an effective amount of a compound according to one of Claims 1 to 16 and/or pharmaceutically usable salt or solvate thereof, and
(b) an effective amount of a further anticancer agent.
25. Pharmaceutical composition according to Claim 23, wherein the at least one anticancer agent is selected from alkylating agents, platinum compounds, topoisomerase inhibitors, poly-(ADP-ribose)-polymerase (PARP) inhibitors, ATR (*ataxia* telangiectasia and Rad3 related) inhibitors, anticancer antibiotics and alpha emitters.
26. The use of a kit according to claim 24, wherein the at least one anticancer agent is selected from alkylating agents, platinum compounds, topoisomerase inhibitors, poly-(ADP-ribose)-polymerase (PARP) inhibitors, ATR (*ataxia* telangiectasia and Rad3 related) inhibitors, anticancer antibiotics and alpha emitters.